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Abstract
Low-dose metronomic (LDM) chemotherapy is emerging as an alternative or supplemental dosing strategy to con-
ventional maximum tolerated dose (MTD) chemotherapy. It is characterized primarily, but not exclusively, by anti-
angiogenic mechanisms of action and the absence of high-grade adverse effects commonly seen with MTD
chemotherapy. However, similar to other anticancer therapies, inherent resistance to LDM chemotherapy is com-
mon. Moreover, even tumors that initially respond to metronomic regimens eventually develop resistance through
mechanisms that are as yet unknown. Thus, we have developed in vivomodels of PC-3 human prostate cancer cells
resistant to extended LDM cyclophosphamide therapy. Such PC-3 variants show stable resistance to LDM cyclo-
phosphamide in vivo yet retain in vitro sensitivity to 4-hydroperoxy-cyclophosphamide (precursor of the active cyclo-
phosphamidemetabolite 4-hydroxy-cyclophosphamide) and other chemotherapeutic agents, namely, docetaxel and
doxorubicin. Moreover, LDM cyclophosphamide–resistant PC-3 variants remain sensitive to MTD cyclophospha-
mide therapy in vivo. Conversely, PC-3 variantsmade resistant in vivo toMTD cyclophosphamide show varying levels
of resistance to metronomic cyclophosphamide when grown in mice. These results and additional studies of var-
iants of the breast cancer cell line MDA-MB-231 suggest that resistance to LDM cyclophosphamide is a distinct
phenomenon from resistance to MTD cyclophosphamide and that LDM cyclophosphamide administration does
not select for MTD chemotherapy resistance. As such, our findings have various implications for the clinical use
of metronomic chemotherapy.
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Introduction
The concept of antiangiogenic therapy has been validated in a number
of phase 3 clinical trials involving advanced,metastatic stages of various
tumor types [1–3]. However, the improvements achieved to date with
such therapy are only incremental. Inherent or acquired therapeutic
resistance is among the reasons for this limited progress [4,5].
Mechanisms of resistance to antiangiogenic therapies that are
emerging from preclinical studies seem, in many cases, to be distinct
from chemotherapy drug resistance but remain poorly understood.
Four major, mutually nonexclusive categories of resistance have been
described [4–7]: 1) evasive resistance, i.e., activation of alternative/
redundant angiogenic pathways; 2) vascular co-option, i.e., enhanced
ability for infiltrative tumor progression depending on the preexisting
Abbreviations: LCR, low-dose metronomic cyclophosphamide–resistant PC-3 variants;
LDM, low-dose metronomic (chemotherapy); MCR, maximum tolerated dose cyclo-
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vasculature of the tumor-surrounding host tissue rather than neoangio-
genesis; 3) reduced vascular dependence, i.e., successful tumor cell ad-
aptation to the hostile microenvironment resulting from long-term
antiangiogenic therapy, characterized by oxygen, nutrient, and growth
factor deprivation [8,9]; and 4) rapid vascular remodeling resulting in
more mature vessels, which tend to be less responsive to antiangiogenic
drugs compared with newly formed immature capillaries. Although
the tumor vasculature is the primary target of antiangiogenic therapies,
the first three of the aforementioned mechanisms of resistance have
in common that tumor cells play a decisive role in contributing to or
mediating such resistance, either by facilitating treatment-resistant
neoangiogenesis or by obtaining growth characteristics that enable
them to progress in the absence of neoangiogenesis.
Whereas MTD chemotherapy affects primarily tumor cells, low-dose
metronomic (LDM) chemotherapy (i.e., frequent—often daily—
extended administration of small doses of conventional chemothera-
peutic drugs without major breaks) is thought to operate primarily
through antiangiogenic effects [10], although some additional mecha-
nisms have been implicated [11]. Promising preclinical LDM chemo-
therapy results [12–16] have been confirmed in an increasing number
of phase 2 clinical trials of a broad range of advanced tumor types
[11,17–20] and in two randomized phase 3 trials of early stage
lung and breast cancer, involving extended (up to 2 years) daily oral
tegafur/uracil (i.e., UFT) adjuvant therapy [21,22]. In addition,
while a number of phase 3 trials applying LDM regimens in various
clinical scenarios are currently recruiting patients (www.clinicaltrials.
gov) [23], metronomic cyclophosphamide (± methotrexate) therapy
has been adopted as a treatment option for advanced breast cancer
by the European Society for Medical Oncology [24]. Aside from clin-
ical benefits of applying LDM regimens, using oral drugs such as cy-
clophosphamide, UFT, or capecitabine in a metronomic manner
comes along with an excellent safety profile [10,11,25,26]. Further-
more, metronomic administration of a given cytotoxic agent may re-
sult in beneficial antitumor effects even in tumors resistant to MTD
regimens of the same drug [12,27,28]. However, as is the case with
other anticancer therapies, inherent or acquired therapeutic resistance
is among the limitations of LDM therapy. Moreover, there are con-
cerns that the use of LDM therapy could facilitate rapid therapeutic
resistance per se and to subsequent MTD chemotherapy [29,30].
Thus, to enable comparative studies of resistance to LDM versus
MTD chemotherapy, we derived variants of the human prostate cancer
cell line PC-3, and the human breast cancer cell line MDA-MB-231,
made resistant in vivo to either LDMorMTD cyclophosphamide ther-
apy. These two tumor models respond both to LDM and to MTD cy-
clophosphamide therapy, which makes them ideal to study therapeutic
resistance. Our results show that acquired in vivo resistance to metro-
nomic cyclophosphamide is a stable and transplantable (i.e., tumor
cell-intrinsic) phenotype. However, resistance to LDM cyclophospha-
mide does not involve cross-resistance to MTD cyclophosphamide
therapy or other cytotoxic agents, namely, docetaxel and doxorubicin.
These findings have implications on how to optimize the benefit of
LDM regimens in various clinical circumstances.
Materials and Methods
Materials and Reagents
Cyclophosphamide, docetaxel, and doxorubicin were obtained from
the institutional pharmacy. 4-OOH-cyclophosphamide was a gift of
Dr S.M. Ludeman (Duke University, Durham, NC).
Animal Procedures
PC-3 human prostate cancer cells (ATCC,Manassas, VA) weremain-
tained in a humidified atmosphere of 5% CO2 at 37°C in Dulbecco’s
modified Eagle medium supplemented with 5% fetal bovine serum.
A total of 2 × 106 cells were injected subcutaneously into the flanks
of 6- to 8-week-old male athymic nude mice (Harlan, Indianapolis,
IN). Tumor size was assessed using calipers and the formula (0.5 ×
[L × W 2]), where L and W represent the largest and the smallest tu-
mor diameter (mm), respectively [31]. Growth inhibition (%) of
individual tumors was calculated when the mean tumor size of the
control group reached around 1000 mm3 and by applying the for-
mula (100 × [1 − (volume of treated tumor / mean tumor volume in
control mice]).
We initiated treatment at an average tumor size of 200 mm3 by
using the following regimens (n = 5 mice per treatment cohort)
[14]: 1) LDM cyclophosphamide: 20 mg/kg per day continuously
administered through the drinking water; 2) MTD cyclophospha-
mide: 150 mg/kg on day 1 and 100 mg/kg on days 3 and 5 admin-
istered intraperitoneally (21-day treatment cycles); and 3) normal
saline control.
To derive treatment-resistant PC-3 variants, tumors that had de-
veloped therapeutic resistance were resected, dissociated mechan-
ically and enzymatically as previously described [31], and adapted to
tissue culture.
The HER-2/neu expressing met2 and LM2-4H2N variants of the
human breast cancer cell line MDA-MB-231 were derived and main-
tained as described previously [32]. To obtain LDM cyclophosphamide–
resistant met2, we implanted 2 × 106 met2 cells into the inguinal
mammary fat pad of severe combined immunodeficient mice pur-
chased fromCharles River Canada (Saint-Constant, Quebec, Canada).
Tumors were surgically removed when they reached an average size of
500 mm3 to allow metastatic progression. Three weeks after surgery,
treatment with LDM cyclophosphamide was initiated as outlined
above. Next, we resected the lungs of mice with treatment-resistant
lung metastases to derive LDM cyclophosphamide–resistant met2
cells. By applying the same procedure, we also obtained MTD cyclo-
phosphamide–resistant and lung metastatic variants of LM2-4H2N
[32]. Because of the high sensitivity of severe combined immunodefi-
cient mice to alkylating agents such as cyclophosphamide, we reduced
the MTD dose to 70 mg/kg administered on days 1, 3, and 5 of each
21-day treatment cycle.
Proliferation Assays
PC-3 and variants were plated in 96-well plates (1500 cells per well),
incubated overnight, and then exposed to 4-OOH-cyclophosphamide
(a precursor of the active cyclophosphamide metabolite 4-OH-
cyclophosphamide) for 6 days with daily medium/drug changes,
as described previously [33]. Thereafter, the cells were pulsed for
4 hours with 2 μCi per well of methyl-[3H]-thymidine (Amersham,
Piscataway, NJ), frozen, and stored (−20°C). After thawing and harvest-
ing the cells, UniFilter GF/C plates (Perkin-Elmer, Boston, MA) were
read in a TopCount NXT microplate scintillation counter (Packard,
Meriden, CT).
For proliferation assays of PC-3 treated with docetaxel or doxorubi-
cin and of met2 and LM2-4H2N treated with 4-OOH-cyclophospha-
mide, we plated 5000 cells per well and added drug-containing
medium the next day. Relative cell numbers were assessed 3 days later
by methylene blue staining [31].
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Colony Formation Assays
PC-3 and variants were either incubated for 6 days in the presence of
0.5 or 1 μM4-OOH-cyclophosphamide, or saline control, as outlined
above, or for 1 hour at 25, 50, or 100 μM4-OOH-cyclophosphamide.
Thereafter, 4-OOH-cyclophosphamide–containing media were re-
moved, and the cells were rinsed with PBS, trypsinized, and replated
at various concentrations. After 12 days, cells were stained with crystal
violet, and colonies (>50 cells) were counted. The surviving fraction
was calculated as the ratio of the plating efficiency of drug-treated cells
to the plating efficiency of untreated cells.
Measurement of Aldehyde Dehydrogenase and Cytochrome
3A4 Activity
Lysates of PC-3 and variants prepared in 100 mM Tris buffer
(pH 8.0) were analyzed for their aldehyde dehydrogenase activity using
the method by Bostian and Betts, as described previously [34,35].
Cytochrome 3A4 activity was determined in microsomal preparations
of PC-3 and variants by applying the P450-Glo CYP3A4 Assay Kit
(Promega Corporation, Madison, WI) and following the manufac-
turer’s instructions [34].
Statistical Analyses
One-way analysis of variance (ANOVA; with Newman-Keuls mul-
tiple comparison test) and t tests were performed as indicated, by using
PRISM Version 4.00 software (GraphPad, San Diego, CA) and apply-
ing a two-sided level of significance set at P < .05.
Results
Derivation of LDM and MTD Cyclophosphamide–Resistant
PC-3 Variants
Previous experiments indicated that PC-3 variants derived from
small relapsing tumors removed at first signs of progression (i.e., tu-
mors that would be considered as “stable disease” in clinical terms),
after an initial response to LDM cyclophosphamide, remain sensitive
to the same treatment when implanted into a new host [14]. To obtain
resistant variants, we therefore decided to extend the period of treat-
ment for as long as possible and to resect tumors near the end point as
per institutional guidelines (∼1500 mm3), followed by adaptation to
tissue culture as previously described (Figures 1 and 2A) [31]. Such
LDMcyclophosphamide–resistant PC-3 variants, or “LCRs,” show re-
sistance to metronomic cyclophosphamide therapy when reimplanted
into new mice (Figure 2, B–D). This in vivo resistance phenotype
is stable and maintained after prolonged in vitro (10 passages;
Figure 2C ) and repeat in vivo passages (Figure 2D; LCR2.2). In con-
trast, in vivo passage by itself does not result in the development of
resistance to LDM cyclophosphamide therapy. In fact, PC-3 variants
obtained after in vivo passage(s) of PC-3 in normal saline–treatedmice,
termed “NS,” remain sensitive to LDM cyclophosphamide therapy
(Figure 2D; NS1.1 and NS2.4).
By applying a similar procedure as outlined for LDMcyclophospha-
mide, we also derived the MTD cyclophosphamide–resistant
(“MCRs”) PC-3 variants, MCR2 and MCR3. Briefly, after long-term
growth suppression of PC-3 xenografts by MTD cyclophosphamide
therapy rapid tumor recurrence was observed after a total of six
(MCR3) or eight (MCR2) treatment cycles (Figure 3A). At that time,
xenograft tissue was resected and adapted to tissue culture. When re-
implanted, MCR2 and MCR3 xenograft growth is slowed somewhat
in mice subjected to MTD cyclophosphamide therapy compared with
mice receiving normal saline control. However, MCR2 andMCR3 tu-
mors do not show the profound and sustained regression seen with the
parental PC-3 line (Figure 3, B–D).
In Vitro Resistance and Cross-resistance Testing
To compare in vivo and in vitro (i.e., tumor cell intrinsic) resistance
behavior to cyclophosphamide, we first exposed PC-3 and a number of
the obtained resistant variants to a MTD-like 1-hour treatment with
micromolar doses (1-100 μM) of 4-OOH-cyclophosphamide, fol-
lowed by plating for a colony formation assay (Figure 4A). Whereas
MCR2 and MCR3 showed clear signs of resistance to 4-OOH-
cyclophosphamide under these circumstances, the responses of
LCR1.1 and LCR2.2 were equivalent to corresponding NS1.1 and
Figure 1. Derivation of PC-3 variants resistant to LDM cyclophosphamide (CPA) therapy: LDM cyclophosphamide treatment (20 mg/kg
per day per os) [14] of subcutaneous PC-3 xenografts was started when tumors reached 200 mm3. After initial regression, tumor growth
eventually resumed. Recurrent tumors were harvested and adapted to tissue culture. LDM cyclophosphamide–resistant PC-3 variants
(LCR1) were then subjected to another round of in vivo selection yielding LCR2 variants.
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NS2.4 control variants. Next, we treated LCR1.1, LCR2.2, corre-
sponding control cells, and MCR2 (the PC-3 variant with the highest
degree of 4-OOH-cyclophosphamide resistance as found in the con-
ventional colony formation assay) with low (i.e., ≤1 μM) concentra-
tions of 4-OOH-cyclophosphamide in a metronomic-like 6-day
proliferation assay, as described previously [33]. In this assay, neither
LCR1.1 nor LCR2.2 showed resistance to 4-OOH-cyclophospha-
mide. However, the growth of MCR2 was significantly less inhibited
by the 6-day 4-OOH-cyclophosphamide treatment than any other cell
line tested (Figure 4B). The same panel of PC-3 variants was also sub-
jected to colony formation assays after exposure to the 6-day 4-OOH-
cyclophosphamide treatment schedule. Again, MCR2 cells showed
superior colony formation properties compared with all other PC-3
variants tested (Figure 4C ). In contrast, the responses of LCR1.1
and LCR2.2 were equivalent to corresponding NS1.1 and NS2.4
control variants. Together, these results suggest that in vivo–acquired
resistance to metronomic cyclophosphamide therapy does not pro-
mote classic drug resistance to cyclophosphamide in PC-3.
To study the phenomenon of differential resistance to LDM versus
MTD cyclophosphamide in another tumor model, we compared the
growth of met2 and LM2-4H2N human breast cancer cells exposed to
4-OOH-cyclophosphamide with the growth of corresponding variants
made resistant to LDM and MTD cyclophosphamide. As detailed in
the Materials and Methods section, treatment-refractory met2 and
LM2-4H2N cells were derived from spontaneous lung metastases,
which had developed under treatment with LDM (met2) or MTD
(LM2-4H2N) cyclophosphamide therapy. Similar to PC-3 and LCRs,
LDM cyclophosphamide–resistant met2 did not show resistance to
4-OOH-cyclophosphamide when compared with parental met2 in a
proliferation assay (Figure 4D). In contrast,MTD cyclophosphamide–
resistant LM2-4H2N variants have a proliferative advantage compared
with LM2-4H2N when exposed to 4-OOH-cyclophosphamide
Figure 2. In vivo testing of parental PC-3 and variants with acquired resistance to LDM cyclophosphamide: Established (∼200 mm3)
xenografts were treatedwith LDM cyclophosphamide (▴; 20mg/kg per day per os),MTD cyclophosphamide (⋄; 150mg/kg intraperitoneallyon day 1 and 100mg/kg on days 3 and 5; 21-day treatment cycles), or saline control (•). (A) PC-3 xenograftswere sensitive to LDMandMTD
cyclophosphamide (P < .001 saline vs LDM and MTD cyclophosphamide, and P > .05 LDM vs MTD cyclophosphamide, day 44; P < .01
LDM vsMTD cyclophosphamide, day 79). (B) The selected LCR1.1 variant was resistant to LDM cyclophosphamide therapy (▴, P> .05 vssaline, day 63) but retained sensitivity to MTD cyclophosphamide (⋄, P < .05 vs saline and LDM cyclophosphamide, day 63). (C) LCR1.1
resistance to LDMcyclophosphamide (▴) wasmaintained after 10 in vitro passages of LCR1.1 cells (P> .05 saline vs LDMcyclophosphamide).(D) LDM cyclophosphamide yielded similar tumor growth inhibition in PC-3 and control variants NS1.1 and NS2.4 (i.e., PC-3 passaged in vivo
in mice subjected to normal saline). However, the antitumor effects of LDM cyclophosphamide were significantly reduced in LCR1.1
and LCR2.2 variants. nsP > .05, *P < .05, **P < .01 (t test). CPA indicates cyclophosphamide.
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(Figure 4D). The reason why resistance to 4-OOH-cyclophosphamide
in these cells is not appreciated over a larger drug concentration range
remains to be investigated.
Aldehyde dehydrogenase and cytochrome 3A4 are critically in-
volved in cyclophosphamide biotransformation and can contribute
to treatment resistance [34,36]. Therefore, we determined aldehyde
dehydrogenase activity in lysates of PC-3 and variants. Figure 4E
shows that the enzymatic activity of LCR did not differ significantly
from the activity measured in PC-3 and NS variants. Otherwise, al-
though increased tumor cell aldehyde dehydrogenase activity has been
described as a potential mechanism of resistance to cyclophosphamide
through increased drug detoxification, this does not apply to MCR2.
Furthermore, despite being reduced in microsomal preparations of
LCRs, NS variants and MCR2 compared with PC-3, the activity of
cytochrome 3A4 (i.e., an enzyme involved in cyclophosphamide acti-
vation) does not seem to correlate with the resistance properties of the
various PC-3 variants (Figure 4F ).
Next, we asked whether LCRs display signs of resistance to classes of
chemotherapeutic drugs other than alkylating agents such cyclophospha-
mide. Because taxanes and topoisomerase II inhibitors are commonly
used for the treatment of advanced prostate cancer [37,38], we sub-
jected the panel of PC-3 and variants to docetaxel as well as doxorubicin
in proliferation assays. Neither LCR1.1 nor LCR2.2 displayed signs
of cross-resistance to these two agents (Figure 5, A and B). Given that
the described primary mechanisms of resistance to cyclophosphamide,
docetaxel, and doxorubicin differ [39], it is not unexpected that MCR2
cells are devoid of cross-resistance to docetaxel or doxorubicin.
In Vivo Cross-resistance Testing
The in vitro results suggested that LCR xenografts retain sensitivity
to MTD cyclophosphamide therapy. Indeed, MTD cyclophospha-
mide therapy resulted in comparable growth inhibition of PC-3,
LCR1.1, and NS1.1 tumors (Figure 5C ). Although growth inhibition
of LCR2.2 tumors by MTD cyclophosphamide is less pronounced
Figure 3. Derivation of PC-3 variants resistant to MTD cyclophosphamide therapy. (A) To obtain MTD cyclophosphamide–resistant PC-3
variants, established subcutaneous PC-3 xenografts were subjected to MTD cyclophosphamide therapy (open triangles). Compared with
tumors treatedwith normal saline (•),MTDcyclophosphamide therapy resulted in sustained tumor regression. However, after six and eight
treatment cycles, respectively, the MTD cyclophosphamide–resistant variants MCR3 (▿) and MCR2 (▵) emerged and were adapted totissue culture. In vivo reexposure revealed marked resistance of MCR2 (B) and MCR3 (C) to MTD cyclophosphamide treatment compared
with the highly sensitive parental PC-3 (•, saline control; open triangles, MTD cyclophosphamide). (D) Tumor growth inhibition calculated
from the previously mentioned xenograft studies using MCR2 andMCR3 reveals significantly diminished antitumor effects of MTD cyclo-
phosphamide in these PC-3 variants compared with parental PC-3. **P < .01 (t test). CPA indicates cyclophosphamide.
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compared with PC-3 xenografts, there is no significant difference in
the treatment response of LCR2.2 and the corresponding control cell
line NS2.4. The latter suggests that repeated in vivo passage rather than
previous LDM CPA exposure may be the reason for the slightly re-
duced antitumor effects of MTD cyclophosphamide in LCR2.2.
Tumor cell lines resistant to MTD doses of a given chemotherapeu-
tic drug have been shown to be sensitive tometronomic administration
of the same agent [12,27]. The resistant lines used in these publications
were either obtained by long-term in vitro selection, transfection of
genes involved in drug resistance (i.e., mdr-1), or administration of
Figure 4. In vitro analysis of cyclophosphamide-resistant tumor cell variants. (A) The colony-forming properties of LCR1.1 and LCR2.2
assessed after exposure to high-dose 4-OOH-cyclophosphamide for 1 hour did not differ compared with PC-3 and control variants (i.e.,
NS1.1 and NS2.4). Conversely, MCR2 and MCR3 colony formation was significantly superior under these conditions. Similarly, prolif-
eration assays (B) and colony-forming assays (C) after metronomic-like treatment with low doses of 4-OOH-cyclophosphamide (≤1 μM
for 6 days) revealed therapeutic resistance of MCR2. In contrast, the LDM cyclophosphamide–resistant variants LCR1.1 and LCR2.2 did
not display such in vitro cyclophosphamide resistance. (D) An LDM cyclophosphamide–resistant variant of the human breast cancer cell
line met2 does not have a proliferative advantage over parental cells in the presence of 4-OOH-cyclophosphamide, in contrast to MTD
cyclophosphamide–resistant LM2-4H2N cells. (E) PC-3, LCR as well as NS variants, and MCR2 did not significantly differ from each other
with respect to aldehyde dehydrogenase activity, an enzyme critically involved in cyclophosphamide detoxification. (F)Whereas the activity
range of cytochrome 3A4 (a cyclophosphamide activating enzyme) varies around five-fold considering PC-3 and all variants thereof tested,
the cytochrome 3A4 activity profile does not seem to be related to the response to LDMand/orMTD cyclophosphamide. ***P< .001 (one-
way ANOVA with Newman-Keuls multiple comparison test).
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supralethal doses of cytotoxics (followed briefly afterward by tumor cell
passage into a fresh host). However, to mimic the manner in which
patients’ tumors acquire resistance during the course of treatment,
our selection process occurred in the same host exposed to repeat
MTD cyclophosphamide treatment cycles. We therefore asked
whether the derived MCR2 and MCR3 variants retained sensitivity
to metronomic cyclophosphamide. Whereas MCR3 tumor xenografts
were almost completely resistant to LDM cyclophosphamide therapy,
the growth-inhibitory effects of this regimen in MCR2 tumors is
around 50% compared with PC-3 (although this result does not reach
statistical significance, in part because of high intertumor variability;
Figure 5D). Thus, based on these results, we conclude that resistance
to MTD chemotherapy using a given drug cannot be overcome uni-
versally by applying the same drug in a metronomic manner.
Discussion
Antiangiogenic therapies, including metronomic chemotherapy, are
susceptible to inherent or acquired treatment resistance, as is the norm
for other anticancer therapies [1,4]. Here we show that cyclophospha-
mide can generate dramatically different resistance phenotypes,
depending on the dose and schedule of treatment. Thus, PC-3 cells
made resistant in vivo to MTD cyclophosphamide therapy show stable
resistance to cyclophosphamide in vitro and in vivo. Conversely, cells
made resistant in vivo to metronomic cyclophosphamide administra-
tion retain sensitivity to cyclophosphamide, docetaxel, and doxorubi-
cin in vitro and to MTD cyclophosphamide in vivo. Similarly, LDM
cyclophosphamide–resistant met2 breast cancer cells do not show
evidence of classic cyclophosphamide resistance.
It is not without precedent that the mode of chemotherapy admin-
istration can affect the mechanisms of action and hence of resistance
to chemotherapeutics. Indeed, 5-fluorouracil preferentially incorpo-
rates into RNA during bolus administration in contrast to preferential
incorporation into DNA when applying infusional regimens. This
schedule-dependent drug behavior could explain the absence of com-
plete cross-resistance between these regimens [40]. However, our re-
sults seen with LDM cyclophosphamide differ from the findings with
5-fluorouracil because both bolus and infusional 5-fluorouracil are
usually used at MTD doses. In other words, these 5-fluorouracil regi-
mens are intended to directly target the tumor parenchyma, whereas
LDM chemotherapy likely affects primarily the tumor vasculature [10].
Arguments raised against the use of below-MTD, “suboptimal”
doses of chemotherapeutic agents include reduced antitumor efficacy
Figure 5. Cross-resistance testing: Proliferation assays using methylene blue staining of PC-3 variants with acquired resistance to LDM or
MTD cyclophosphamide did not reveal evidence for cross-resistance to docetaxel (A) or doxorubicin (B). Interestingly, compared with the
other cell variants tested, LCR2.2 is significantly more sensitive to docetaxel (P< .001 at 0.1, 1, and 10 pM of docetaxel, one-way ANOVA).
(C) Whereas the in vivo effects of MTD cyclophosphamide therapy were comparable in PC-3, LCR1.1, and NS1.1, the antitumor activities of
MTD cyclophosphamidewere less pronounced in both LCR2.2 and NS2.4 comparedwith that in PC-3. However, the comparable therapeutic
responses in LCR2.2 and NS2.4 suggest that this phenomenon may be related to repeated in vivo passage. (D) LDM cyclophosphamide–
related growth inhibition of MCR2 and MCR3 tumors is reduced compared with PC-3. Because of the large intertumor variability regarding
treatment response, the trendwithMCR2 did not reach statistical significance. nsP> .05, *P< .05 (t test). CPA indicates cyclophosphamide.
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and rapid emergence of drug resistance [29,30]. The latter would be of
particular concern in cases of combined metronomic and conventional
chemotherapy, or the early use of metronomic chemotherapy (i.e.,
LDM therapy in the [neo]adjuvant setting or as first-line therapy for
advanced disease). The absence of classic cyclophosphamide resistance
in LCRs and LDM cyclophosphamide–resistant met2 cells reported
herein and our previous observations of beneficial combinations of
LDM and MTD chemotherapy are therefore very reassuring [41].
Furthermore, whereas LDM cyclophosphamide chemotherapy in-
duces severe hypoxia in PC-3 xenografts and Dunning prostate
R3327-AT tumors [31,42], which in turn could contribute to the de-
velopment of multidrug resistance [43], the lack of cross-resistance of
LCRs to docetaxel and doxorubicin does not support this notion in our
model. As such, our results challenge concerns expressed that metro-
nomic chemotherapy might compromise the later use of conventional
chemotherapy regimens.
When patients are screened for clinical trial eligibility, LDMchemo-
therapy is usually regarded as a line of cytotoxic therapy equivalent to
MTD chemotherapy. In other words, previous LDM therapy could
make patients ineligible for certain clinical trials. In the light of the re-
sults presented herein, this policy may need to be reconsidered, at least
in the case of LDMchemotherapy using cyclophosphamide. However,
preliminary findings suggest that the phenomenon of differential resis-
tance to LDMandMTDchemotherapy administrationmay also apply
to other classes of cytotoxic agents such as topoisomerase I inhibitors.
For example, human ovarian cancer xenografts that have acquired re-
sistance to long-term daily LDM oral topotecan therapy continue to
be responsive to MTD topotecan treatment (K. Hashimoto and R.S.
Kerbel, unpublished observations).
Metronomic administration of a given chemotherapeutic agent has
been proposed as a means to overcome classic drug resistance to the
same agent in vivo [12,27].However, the resistant variants used in such
studies were selected by using either various in vitro selection protocols
or repeat ex vivo passages of tumor cells after supralethal doses of cyto-
toxics (as detailed in the Results section). These methods are distinct
from the selection procedure applied herein. Because the nature of the
selection procedure can impact on the in vivo behavior of the resulting
resistant cell lines [44], this offers a potential explanation why the anti-
tumor effects of LDM cyclophosphamide are very limited in MCR2
and almost nonexistent in MCR3. In fact, MTD chemotherapy usu-
ally results not only in direct antitumor effects but also in collateral
vascular damage [10]. Although these antivascular effects are relatively
short-lived because of rapid vascular repair [45], if they are recurring,
they might contribute to the selection of tumor cells capable of with-
standing the consequences of long-term antiangiogenic therapies. This
could explain why the benefits of using metronomic regimens and
other antiangiogenic strategies are less pronounced in patients who
have undergone multiple previous rounds of chemotherapy [46,47].
The results summarized herein contribute to a growing body of
(pre)clinical evidence that, under certain circumstances, resistance to
antiangiogenic therapies may depend largely on tumor cell intrinsic
properties [4,5,48,49]. In fact, the concepts of vascular co-option
and reduced vascular dependence suggest that antiangiogenic therapy-
refractory tumor progression may occur in the absence of neoangiogen-
esis. Whereas vascular co-option has been described almost exclusively
in malignant astrocytomas [49], the phenomenon of reduced vascular
dependence is expected to apply to a broader range of tumor types
[31,48,50]. Previous studies with PC-3 xenografts had suggested that
reduced vascular dependence contributes to resistance to LDM cyclo-
phosphamide in this tumor model [31]. Furthermore, we showed that
the tumor vasculature does not seem to develop resistance to long-term
LDMcyclophosphamide therapy [34]. Similarly, LDM cyclophospha-
mide therapy lacks significant antitumor activity in LCR tumors but
decreases microvessel density in LCR tumors to the same extent as seen
with PC-3 and NS xenografts (A. Kouri and U. Emmenegger, unpub-
lished observations).
Using the tumor models described in this report, we are currently
studying the mechanisms of resistance to LDM compared with MTD
cyclophosphamide chemotherapy. Regarding the former, a recent pro-
teomic analysis by Thoenes et al. revealed several interesting candidate
genes [51]. Ultimately, the results of such studies may suggest means of
improving the antitumor activities of metronomic chemotherapy and
reveal candidate markers that predict resistance to such therapy as well
as to other antiangiogenic treatment strategies.
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